GGrantIndex
← Leaderboards

Xuefeng Liu

Ohio State University

$6,815,737
Attributed
$6,815,737
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.6M · FY201325
$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,815,737 · 5

By mechanism

R01$3,512,419 · 2
U01$1,783,393 · 1
R33$1,153,979 · 1
R21$365,946 · 1

Top collaborators

No co-investigators on record.

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Response

Research focus

ResponseCellsCancer PatientProtocols DocumentationSuccessTechnologyEuropeanMalignant NeoplasmsMutationLaboratoriesTumorCell ModelUrologyTherapeutic AgentsCancer CenterIn VitroSpecimenPatient ResponseDiagnosisOperative Surgical ProceduresCell Culture TechniquesMedicalMortalityPaper

Grant awards (16)

Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer$1,080,844
U01 · FY2025 · CA · contact PI
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men$537,842
R01 · FY2025 · CA · contact PI
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men$510,952
R01 · FY2024 · CA · contact PI
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer$342,268
U01 · FY2024 · CA · contact PI
Developing Functional Human Cell Models to Study Initiation and Progression of Prostate Cancer between AA and EA men$537,842
R01 · FY2023 · CA · contact PI
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics$383,927
R33 · FY2023 · CA · contact PI
Evaluation of Pre-Analytical Factors of Urine Samples for Urine Cancer Cell Cultures (UCCC) --A Non-Invasive Biomarker – in Monitoring Response and Recurrence of Bladder Cancer$360,281
U01 · FY2023 · CA · contact PI
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)$471,066
R01 · FY2022 · CA · contact PI
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics$379,392
R33 · FY2022 · CA · contact PI
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)$482,155
R01 · FY2021 · CA · contact PI
Validating Urine Derived Cancer Cells (UDCC) -- Non-Invasive and Living Liquid Biopsies -- in Bladder Cancer Clinics$390,660
R33 · FY2021 · CA · contact PI
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)$365,015
R01 · FY2020 · CA · contact PI
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)$114,328
R01 · FY2020 · CA · contact PI
Conditionally Reprogrammed Cell Model for Castration-Resistant Prostate Cancer (CRPC)$493,219
R01 · FY2019 · CA · contact PI
NON-CANONICAL FUNCTIONS OF HTERT IN CELL IMMORTALIZATION BY HPV$196,840
R21 · FY2014 · CA · contact PI
NON-CANONICAL FUNCTIONS OF HTERT IN CELL IMMORTALIZATION BY HPV$169,106
R21 · FY2013 · CA · contact PI